Bioenvision to Present at the Rodman & Renshaw Techvest Global Healthcare Conference; Presentation Scheduled for Thursday, May 13, 2004 at 2:50 PM GMT, 9:50 AM EDT.Business Editors/Health/Medical Writers Techvest Global Healthcare Conference 2004 NEW YORK--(BUSINESS WIRE)--May 10, 2004 Bioenvision, Inc. (Amex:BIV BIV Bivouac BiV Biventricular BIV Bovine Immunodeficiency Virus BIV Built-in Variable (plumbing) ) today announced that Dr. Christopher B. Wood, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bioenvision, is scheduled to present at the Rodman & Renshaw Techvest Global Healthcare Conference on Thursday, May 13, 2004 at 2:50 PM GMT (Greenwich Mean Time) See UTC. GMT - Universal Time 1 (9:50 AM EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT ) at Claridge's Hotel in London, England. Dr. Wood will provide a corporate overview and an update on the European development of clofarabine in pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. and adult acute leukemias Leukemias, Acute Definition Leukemia is a cancer that starts in the organs that make blood, namely the bone marrow and the lymph system. Depending on their characteristics, leukemias can be divided into two broad types. as well as in solid tumors. Dr. Wood will also discuss the continued development of Modrenal, which is approved and marketed for advanced post-menopausal breast cancer in the United Kingdom and which is soon to start a prostate cancer trial in the U.S. The presentation will be webcast live and can be accessed from the Company's website, www.bioenvision.com. A replay of the presentation will also be available at the same site. About Bioenvision Bioenvision's (Amex:BIV) primary focus is the development and distribution of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: clofarabine (in co-development with ILEX Ilex a bush bearing berries containing saponins; cause vomiting, diarrhea. Called also holly. Oncology, Inc.), Modrenal(R) (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy), and other products in clinical trials. Bioenvision is also developing anti-infective technologies, including the OLIGON technology; an advanced biomaterial that has been incorporated into various FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved medical devices. For more information on Bioenvision please visit our Web site at www.bioenvision.com. Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Bioenvision's compounds under development in particular; the potential failure of Bioenvision's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioenvision's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioenvision's business, structure or projections; the development of competing products; uncertainties related to Bioenvision's dependence on third parties and partners; and those risks described in Bioenvision's filings with the SEC. Bioenvision disclaims any obligation to update these forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion